Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159020 | 0.78 | ALDH1A1 (0.39) | SLC6A2SLC6A3KDM4EALDH1A1MAPT | |
| SCHEMBL6160110 | 0.76 | KMT2A (0.44) | SLC6A2SLC6A3MAPT | |
| SCHEMBL5219990 | 0.73 | SLC6A3 (0.42) | SLC6A2SLC6A3KDM4EALDH1A1MAPT | |
| SCHEMBL6159495 | 0.65 | MAP3K14 (0.37) | SLC6A2SLC6A3ALDH1A1MAPTSLC6A4 | |
| SCHEMBL5216813 | 0.64 | SLC6A2 (0.48) | SLC6A2SLC6A3KDM4EALDH1A1MAPT | |
| SCHEMBL6160330 | 0.61 | SLC6A3 (0.42) | SLC6A2SLC6A3KDM4EALDH1A1MAPT | |
| SCHEMBL6160368 | 0.58 | PPARG (0.43) | SLC6A2SLC6A3ALDH1A1MAPTSLC6A4 | |
| SCHEMBL4331978 | 0.58 | SLC6A2 (0.68) | SLC6A2SLC6A3SLC6A4KCNH2CYP2D6 | |
| SCHEMBL15335800 | 0.56 | SLC6A2 (0.70) | SLC6A2SLC6A3SLC6A4KCNH2CYP2D6 | |
| SCHEMBL10684465 | 0.56 | SLC6A3 (0.67) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967254-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2005-11-22 | — | — | US | disclosed |
| EP-1542680-A1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES S TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | Amgen Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040058918-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2004-03-25 | — | — | US | disclosed |
| WO-2004022055-A1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES S TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058918-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MAPT, HMGB1 | SLC6A2 1739/4885SLC6A3 2583/4885KDM4E 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.